Kairos Pharma Wins 2026 Pinnacle Award for Cancer Drug Resistance Innovation

Kairos Pharma (NYSE American: KAPA), a clinical-stage biopharmaceutical company, has been honored as an Emerald honoree at the prestigious 2026 Pinnacle Awards for Healthcare. This recognition celebrates the company's innovative strategy to combat cancer drug resistance, a major challenge in oncology treatment. The company's approach focuses on resistance-modulating treatments, with its lead candidate ENV-105 (carotuximab) designed to inhibit tumor resistance pathways and enhance the effectiveness of existing therapies. Kairos Pharma is advancing combination approaches aimed at improving durability of response across multiple cancer indications, positioning itself at the forefront of oncology therapeutics.

Based in Los Angeles, California, Kairos Pharma utilizes structural biology to overcome drug resistance and immune suppression in cancer. The company's lead candidate, ENV-105, is an antibody that targets CD105—a protein identified as a key driver of resistance and disease relapse in response to standard therapy. ENV-105 aims to reverse drug resistance by targeting CD105 and restore the effectiveness of standard therapies across multiple cancer types. Currently, ENV-105 is in a Phase 2 clinical trial for castrate-resistant prostate cancer and a Phase 1 trial for non-small cell lung cancer, addressing significant unmet medical needs. It's important to note that as of the press release date, ENV-105 has not been approved as safe or effective by the United States Food and Drug Administration or any other comparable foreign regulator.

The press release was distributed through InvestorWire, a specialized communications platform that is part of the Dynamic Brand Portfolio at IBN. InvestorWire provides advanced wire-grade press release syndication for private and public companies and the investment community, offering access to a vast network of wire solutions, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement for maximum impact, social media distribution via IBN to millions of followers, and a full array of tailored corporate communications solutions. For more information about Kairos Pharma, investors can visit the company's newsroom at https://ibn.fm/KAPA or view the full press release at https://ibn.fm/ghPJC.